KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EPS (Weighted Average and Diluted) (2016 - 2025)

Sarepta Therapeutics has reported EPS (Weighted Average and Diluted) over the past 11 years, most recently at -$3.93 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 362.0% year-over-year to -$3.93; the TTM value through Dec 2025 reached -$7.14, down 413.16%, while the annual FY2025 figure was -$7.13, 404.7% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$3.93 at Sarepta Therapeutics, down from -$0.5 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.89 in Q2 2025 and troughed at -$4.6 in Q1 2025.
  • A 5-year average of -$0.87 and a median of -$0.5 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 2600.0% in 2025 and fell as far as 1343.24% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.43 in 2021, then grew by 13.29% to -$1.24 in 2022, then surged by 161.29% to $0.76 in 2023, then soared by 97.37% to $1.5 in 2024, then plummeted by 362.0% to -$3.93 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SRPT at -$3.93 in Q4 2025, -$0.5 in Q3 2025, and $1.89 in Q2 2025.